TP53 and glioblastoma: For instance, domain-focused CRISPR screens identified BRD8 as a p53-dependent vulnerability[113], and targeting the bromodomain of BRD8 may be a promising therapeutic strategy for patients with wt-p53 in glioblastoma multiforme (GBM), for which there has been no improvement in treatment for decades.